Isfahan University of Medical Sciences

Science Communicator Platform

Share By
Impact of Age at Onset on Relapse and Disability in Aqp4-Igg Neuromyelitis Optica Spectrum Disorder Publisher Pubmed



Siriratnam P ; Jokubaitis VG ; Van Der Walt A ; Sanfilippo PG ; Zhu C ; Etemadifar M ; Altintas A ; Alasmi A ; Laureys G ; Mecalallana JE ; Foschi M ; Alroughani R ; Gomezfigueroa E ; Habek M Show All Authors
Authors
  1. Siriratnam P
  2. Jokubaitis VG
  3. Van Der Walt A
  4. Sanfilippo PG
  5. Zhu C
  6. Etemadifar M
  7. Altintas A
  8. Alasmi A
  9. Laureys G
  10. Mecalallana JE
  11. Foschi M
  12. Alroughani R
  13. Gomezfigueroa E
  14. Habek M
  15. Khoury SJ
  16. Simo M
  17. Singhal BSG
  18. Jakob GB
  19. Fabispedrini MJ
  20. Soysal A
  21. Kermode AG
  22. Shaygannejad V
  23. Kubala Havrdova E
  24. Millanpascual J
  25. Roos I
  26. Mccombe PA
  27. Nytrova P
  28. Boz C
  29. Surcinelli A
  30. Kalincik T
  31. Patti F
  32. Huda S
  33. Butzkueven H
  34. Monif M
  35. Ozakbas S
  36. Kister I
  37. Naser Moghadasi A
  38. Boz C
  39. Yamout B
  40. Lechner Scott J
  41. Carroll WM
  42. Hardy TA
  43. Vucic S
  44. Reddel S
  45. Ramanathan S
  46. Grandmaison F
  47. Libertinova J
  48. Hradilek P
  49. Luis Sanchez Menoyo J
  50. Ramotello C
  51. Rajda C
  52. Alharbi T
  53. Turkoglu R
  54. Slee M
  55. Willekens B
  56. Vachova M
  57. Houskova J
  58. Mares M
  59. Stetkarova I
  60. Hodgkinson S
  61. Buzzard K
  62. Skibina O
  63. Macdonell R
  64. Lapointe E
  65. Rous Z
  66. Pavelek Z
  67. Shalaby N
  68. Karelis G
  69. Alkhaboori J
  70. Inshasi J
  71. Boggild M
  72. Van Pesch V
  73. Oh J
  74. Recmanova E
  75. Peterka M
  76. Talaat F
  77. Gray O
  78. Csepany T
  79. Mohammad Baghbanian S
  80. Damico E
  81. Skromne E
  82. Yung Hor J
  83. Fatih Yetkin M

Source: Neurology Published:2026


Abstract

Background and Objectives – Previous studies have reported inconsistent findings regarding the impact of age at onset on relapse risk in aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), although older disease onset has been linked to more rapid disability accrual. This is in contrast to multiple sclerosis, where advancing age and older onset are associated with reduced relapse activity, allowing for treatment de-escalation or discontinuation in some older patients. The aim of this study was to clarify the influence of age at onset on relapse risk as well as disability accrual in a large, international cohort of patients with NMOSD.Methods – We conducted a retrospective, multicenter cohort study using the MSBase data registry to evaluate annualized relapse rates (ARRs), time to first relapse, and time to Expanded Disability Status Scale (EDSS) scores of 4 and 6. For inclusion, a diagnosis of AQP4-IgG NMOSD according to the latest iteration of the criteria and availability of the minimum data set were required. Patients were stratified as pediatric onset (<18 years of age), early onset (18–55 years inclusive) or late onset (>55 years of age). Analyses included patients on high-efficacy therapy (HET), those on low-efficacy therapy (LET), and an incident cohort with the first clinical visit within 12 months from disease onset. Predictors of first relapse and EDSS 4/6 thresholds were analyzed using Cox proportional models.Results – Data from 539 patients (42 pediatric, 421 with early onset, 76 with late onset; 85.2% female) with a median age at onset of 35 years (Q1 25.10, Q3 47.60) and a disease duration of 7.42 years (Q1 3.23, Q3 13.10) were analyzed. ARR and time to first relapse were not influenced by age at disease onset. Patients on HET had fewer relapses than those on LET (p < 0.001). Older age was linked to faster disability accumulation. In addition, higher baseline EDSS scores and delayed treatment were independent predictors of future disability.Discussion – Our study demonstrates that while age at onset does not affect relapse risk, older patients experience more rapid disability accrual. These findings underscore the importance of early initiation of effective preventive immunotherapy in all age groups. The primary limitations of this study pertain to its retrospective design and the sole reliance on EDSS for disability assessment. © 2026 American Academy of Neurology
Related Docs
View other Related Docs
1. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis, JAMA Neurology (2018)
2. Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (Nmosd) Five Years After Disease Onset, Journal of Clinical Medicine (2022)
3. Towards Personalized Therapy for Multiple Sclerosis: Prediction of Individual Treatment Response, Brain (2017)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (14)
Fereshteh Ashtari (3)
Other Related Docs
4. Corticosteroid Treatment of Multiple Sclerosis Relapses Is Associated With Lower Disability Worsening Over 5 Years, Journal of Neurology, Neurosurgery and Psychiatry (2025)
5. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years, Neurology (2021)
6. Sex As a Determinant of Relapse Incidence and Progressive Course of Multiple Sclerosis, Brain (2013)
7. Epidemiologic and Clinical Characteristics of Neuromyelitis Optica Spectrum Disorder Patients, a Seven Years Follow-Up Study From Iran, Multiple Sclerosis and Related Disorders (2023)
8. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Neurology (2022)
9. Early Non-Disabling Relapses Are Important Predictors of Disability Accumulation in People With Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis Journal (2023)
10. Prognostic Indicators in Pediatric Clinically Isolated Syndrome, Annals of Neurology (2017)
11. Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With Aqp4-Igg-Positive Nmosd, Neurology (2024)
12. Contribution of Different Relapse Phenotypes to Disability in Multiple Sclerosis, Multiple Sclerosis (2017)
13. Progression Independent of Relapse Activity and Relapse-Associated Worsening in Seronegative Nmosd: An International Cohort Study, Journal of Neurology (2025)
14. Disease Course, Progression and Activity of Neuromyelitis Optica (Nmosd) in Patients Who Were Treated With Rituximab, 6 and 12 Months After Receiving the First Dose of Drug, in Isfahan City, Multiple Sclerosis and Related Disorders (2019)
15. Confirmed Disability Progression As a Marker of Permanent Disability in Multiple Sclerosis, European Journal of Neurology (2022)
16. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)
17. Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study, CNS Drugs (2026)
18. Early Clinical Response and Complications of Therapeutic Plasma Exchange in Central Nervous System Demyelinating Diseases, Journal of Central Nervous System Disease (2024)